Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
Comparison of safety and tolerability with continuous (exenatide once a week) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.